Drug
Ociperlimab
Ociperlimab: highest development phase Phase 2, developed by BeiGene. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ociperlimab NCT04952597 | Phase 2 | Limited Stage Small Cell Lung Cancer |
| Ociperlimab NCT05267054 | Phase 1/2 | Relapsed Diffuse Large B-cell Lymphoma |
| Ociperlimab NCT04047862 | Phase 1 | Locally Advanced and Metastatic Solid Tumors |
Latest
No recent events.
Follow Ociperlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.